Patents Assigned to Pfizer
  • Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer
    Publication number: 20040192727
    Abstract: This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography.
    Type: Application
    Filed: April 14, 2004
    Publication date: September 30, 2004
    Applicant: Pfizer Inc.
    Inventors: R. Mark Guinn, Subramanian Sam Guhan, Karl K. Ng, Derek L. Tickner, Marcus Douglas Ewing, Clifford N. Meltz, Bryan Li, Kees Pouwer
  • NMDA NR2B antagonists for treatment
    Publication number: 20040192763
    Abstract: The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
    Type: Application
    Filed: April 9, 2004
    Publication date: September 30, 2004
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
  • Crystal structures of streptococcus undecaprenyl pyrophosphate synthase and uses thereof
    Publication number: 20040191271
    Abstract: The invention is directed generally to the structure of prenyltransferases, particularly undecaprenyl pyrophosphate synthase, an enzyme important in bacterial cell wall synthesis. The invention relates to the crystal structure of undecaprenyl pyrophosphate synthase from Streptococcus pneumoniae and its interaction with cofactors and ligands. The invention also relates to the structure of ligand and cofactor binding sites of undecaprenyl pyrophosphate synthase.
    Type: Application
    Filed: March 31, 2004
    Publication date: September 30, 2004
    Applicant: Pfizer Inc
    Inventors: Kimberly F. Fennell, Mahmoud N. Mansour, Xiayang Qiu
  • Antiparasitic formulations
    Patent number: 6797701
    Abstract: A long-acting antiparasitic formulation suitable for topical application including: (a) 0.1-50% w/v an avermectin or milbemycin having activity against endo- and/or ectoparasites; (b) 1-50% v/v a di(C2-4 glycol) mono(C1-4 alkyl) ether; (c) an optional antioxidant; and (d) an optional skin acceptable volatile solvent q.s. v/v.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: September 28, 2004
    Assignee: Pfizer Inc.
    Inventors: Timothy Michael Lukas, Stephen Richard Wicks
  • Resorcinol derivatives
    Patent number: 6797731
    Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: September 28, 2004
    Assignee: Pfizer Inc.
    Inventors: Stuart E. Bradley, Eric W. Collington, Matthew C. Fyfe, William T. Gattrell, Joanna V. Geden, Peter J. Murray, Martin J. Procter, Robert J. Rowley, Jonathan G. Williams
  • Treatment of type 1 diabetes with PDE5 inhibitors
    Publication number: 20040186046
    Abstract: The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 12, 2004
    Publication date: September 23, 2004
    Applicant: Pfizer Inc
    Inventors: Gillian Munro Burgess, Earl Michael Gibbs, Christopher Peter Wayman
  • Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
    Publication number: 20040185102
    Abstract: A dosage form comprises (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and a neutral or neutralized acidic polymer and (2) an HMG-CoA reductase inhibitor. The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 23, 2004
    Applicant: Pfizer Inc
    Inventors: Dwayne T. Friesen, David K. Lyon, Douglas A. Lorenz, Rodney J. Ketner, Bruno C. Hancock, Timothy J. McDermott, Ravi M. Shanker
  • Triazole compounds useful in therapy
    Publication number: 20040186091
    Abstract: A compound of formula (I), 1
    Type: Application
    Filed: February 18, 2004
    Publication date: September 23, 2004
    Applicant: Pfizer Inc
    Inventors: Justin Stephen Bryans, Patrick Stephen Johnson, Thomas Ryckmans, Alan Stobie
  • Pharmaceutically active compounds
    Patent number: 6794387
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, X, Y and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: Charlotte Moira Norfor Allerton, Kevin Neil Dack, Mark Ian Kemp
  • Target
    Patent number: 6794192
    Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
  • Succinic acid salts of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
    Patent number: 6794388
    Abstract: The present invention is directed to the succinate salts of 5,7,13-triazatetracyclo[9.3.1.02,10.04,8]-pentadeca-2(10),3,5,8-tetraene and pharmaceutical compositions thereof. The invention is also directed to a process for preparation of the succinate salts.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: September 21, 2004
    Assignee: Pfizer Inc.
    Inventors: George J. Quallich, Lewin T. Wint
  • Efficient synthesis of 5-heteroatom-containing -pyrazoles
    Patent number: 6794512
    Abstract: An efficient synthesis of sulfonyl pyrazoles of formula I: wherein the ring of the formula (R5)-A-(SOmR4), m, R1 through R9 are as defined in the specification, comprising reacting a compound of formula II: wherein the ring of the formula (R5)-A-(SOmR4), m R1 through R9 are as defined above and wherein R10 is halo, (C1-C6)alkyl-SO3—, (C6-C10)aryl-SO3—, (C1-C6)alkyl-SO2—, or (C6-C10)aryl-SO2—; wherein each of said (C1-C6)alkyl component of said (C1-C6)alkyl-SO3— and (C1-C6)alkyl-SO2— radicals may optionally be substituted on any carbon atom by one to six fluoro substituents per (C1-C6)alkyl component; with a compound of formula R3—H, wherein R3 is as defined above, in the presence of a fluoride containing salt and in the presence of a solvent.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: September 21, 2004
    Assignee: Pfizer, Inc.
    Inventors: Andrei Shavnya, Subas M. Sayka, Martha L. Minich, Bryson Rast
  • Benzamide inhibitors of the P2X7 receptor
    Publication number: 20040180894
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: 1
    Type: Application
    Filed: December 30, 2003
    Publication date: September 16, 2004
    Applicant: Pfizer Inc.
    Inventors: Mark A. Dombroski, Allen J. Duplantier
  • Benzimidazole cyclooxygenase-2 inhibitor
    Publication number: 20040181062
    Abstract: This invention provides a compound of the following formula: 1
    Type: Application
    Filed: February 5, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventors: Yoshiyuki Okumura, Yoshinori Murata, Takashi Mano
  • 4"-substituted-9-deoxo-9A-AZA-9A-homoerythromycin a derivatives
    Publication number: 20040180842
    Abstract: The invention relates to a method of preparing compounds of the formula 1
    Type: Application
    Filed: March 26, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventors: Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
  • 3-(1-[3-(1,3-Benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as NEP inhibitors
    Publication number: 20040180941
    Abstract: The invention relates to inhibitors of neutral endopeptidase enzyme (NEP), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of male and female sexual dysfunction, particularly female sexual dysfunction (FSD), especially wherein the FSD is female sexual arousal disorder (FSAD).
    Type: Application
    Filed: March 12, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventor: David Hepworth
  • Novel pyrazine compounds as transforming growth factor (TGF) compounds
    Publication number: 20040180905
    Abstract: Novel pyrazine compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: March 10, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventor: Michael J. Munchhof
  • Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction
    Publication number: 20040180944
    Abstract: 1
    Type: Application
    Filed: March 23, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventors: Mark Edward Bunnage, John Paul Mathias, Stephen Derek Albert Street, Anthony Wood
  • Triazole derivatives useful in therapy
    Patent number: 6790957
    Abstract: The invention provides compounds of formula I, R1—OP(O)(OH)2  I wherein R1 represents the non-hydroxy portion of a triazole antifungal compound of the type comprising a tertiary hydroxy group; or a pharmaceutically acceptable salt thereof. The compounds of the invention are useful in the treatment of fungal infections, and have good aqueous solubility.
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: September 14, 2004
    Assignee: Pfizer, Inc.
    Inventors: Stuart Green, Peter T. Stephenson, Charles W. Murtiashaw
  • Materials for packing nicotine-containing products
    Patent number: 6790496
    Abstract: A material for packaging a nicotine product comprising a polymer based on dimethyl-2,6-naphthalene dicarboxylic or 2,6-naphthalene dicarboxylic acid monomers, such as polyethylene naphtalate (PEN) or polytrimethylene naphtalate (PTN), or a liquid crystal polymer (LPC). The material may be laminated to another polymer or to metal foil.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: September 14, 2004
    Assignee: Pfizer Health AB
    Inventors: Gustav Levander, Anders H. F. Karlsson, Ingemar Hildingsson